Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab

(2020) Caroline R. Baumal et al.   OPHTHALMOLOGY

HAWK and HARRIER

(2020) Pravin U. Dugel et al.   OPHTHALMOLOGY

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

(2019) Pravin U. Dugel et al.   OPHTHALMOLOGY

The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective

(2018) Freekje van Asten et al.   PLoS One

Safety of 5914 intravitreal ziv-aflibercept injections

(2018) Sumit Randhir Singh et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis

(2016) Eric H. Souied et al.   OPHTHALMIC EPIDEMIOLOGY

Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid

(2016) Glenn J. Jaffe et al.   OPHTHALMOLOGY

Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

(2013) Ursula Schmidt-Erfurth et al.   OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease

(2011) Michael Tolentino   SURVEY OF OPHTHALMOLOGY